Genitourinary Cancer

Latest News

Nivolumab/Ipilimumab May Be Most Effective mRCC Treatment, Sunitinib Most Cost-Effective
Nivolumab/Ipilimumab May Be Most Effective mRCC Treatment, Sunitinib Most Cost-Effective

January 18th 2023

A decision model with a 10-year time horizon found that nivolumab plus ipilimumab was the most effective combination for patients with metastatic renal cell carcinoma, but sunitinib was the most cost-effective approach.

Neoadjuvant Split-Dose Chemotherapy Represents Potential New Standard of Care for High-Risk UTUC
Neoadjuvant Split-Dose Chemotherapy Represents Potential New Standard of Care for High-Risk UTUC

January 13th 2023

Nadofaragene Firadenovec Gets Go-Ahead in High-Risk Non–Muscle Invasive Bladder Cancer
Nadofaragene Firadenovec Gets Go-Ahead in High-Risk Non–Muscle Invasive Bladder Cancer

January 3rd 2023

Enzalutamide Inspires Meaningful Delay in PSA Progression For Patients With PSA-Recurrent High-Risk Prostate Cancer
Enzalutamide Inspires Meaningful Delay in PSA Progression For Patients With PSA-Recurrent High-Risk Prostate Cancer

December 3rd 2022

Rogaratinib May Be Effective for Patients With Bladder Cancer and FGFR3 DNA Alterations
Rogaratinib May Be Effective for Patients With Bladder Cancer and FGFR3 DNA Alterations

November 14th 2022

Video Interviews
Podcasts

More News

© 2023 MJH Life Sciences

All rights reserved.